Futura Medical PLC (AIM:FUM, OTC:FAMDF), a pharmaceutical company specialising in innovative sexual health products, has announced OTC Marketing Authorisation for its topical gel Eroxon from the Mexican Secretariat of Health.
With this sign-off, the erectile dysfunction (ED) product can be sold in Mexico without a prescription. It plugs the Futura's fast-acting gel into a large new market, building on the success it has seen in the UK and Belgium.
Eroxon, which overcomes many of the side effects of traditional blue-pill ED drugs, has been signed off for over-the-counter use in the US and is available in Europe, too.
Key markets for expansion include the European Economic Area, the United Kingdom, Switzerland, South Korea, Latin America and the Middle East.
"Following the approval by the US FDA earlier this year, Mexican marketing authorisation opens up another very large and exciting market for Eroxon," said Futura chief executive James Barder.
"Mexico is a vibrant and dynamic market, and we look forward to bringing the benefits of Eroxon to ED sufferers in Mexico with our commercial partner M8."